Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Long-Acting pill could smooth Parkinson's symptoms

NCT ID NCT05036473

Completed Disease control Sponsor: Shanghai WD Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests an extended-release tablet containing carbidopa and levodopa (WD-1603) for people with early Parkinson's disease. The goal is to see if taking the medication three times daily improves motor symptoms and daily living better than a placebo. The trial involves 40 adults aged 30–75 with mild to moderate Parkinson's and compares the drug's effects over 27 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
WD-1603 (carbidopa-levodopa extended-release tablets)
What this could lead to
If successful, this extended-release formulation could provide more stable symptom control for people with early Parkinson's disease, reducing motor fluctuations.
What could go wrong
This is an early phase 2 trial with only 40 participants, so results may not apply to all patients. The drug may cause side effects like nausea or dizziness, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

  • Shanghai Huashan Hospital

    Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.